Overview of Products
AcelRx has two products, Dsuvia and Zalviso. Dsuvia comes in the form of a sublingual tablet to be dissolved under the tongue, containing 30 micrograms of sufentanil. AcelRx has created a proprietary noninvasive delivery method through a one-time use, disposable applicator. Dsuvia is an option for medical professionals to aid in moderate to severe pain management in controlled and distressed settings ranging from postoperative surgery to the battlefield. Dsuvia achieved FDA approval in November of 2018 and is currently in the process of market acceptance and physician recognition, as well as commercialization.